The FDA approved seven new molecular entities in December, bringing the agency’s 2025 total to 46 NMEs — down from 50 in 2024, BioCentury reported. The December approvals spanned multiple therapeutic areas and capped a year that saw a modest decline in overall NME count. The regulatory cadence will remain a key metric for developers planning launches and commercial timelines in 2026.